Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.39 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.39 |
| ▸ | PLA2G5 | P39877 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | SLC6A1 | P30531 | 2/20 | 0.33 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23331817 | 0.85 | PLA2G10 (0.43) | HRH3PLA2G10PLA2G5ALDH1A1SLC6A9 | |
| SCHEMBL16480467 | 0.81 | HRH3 (0.55) | HRH3 | |
| SCHEMBL9891878 | 0.79 | HRH3 (0.41) | HRH3ALDH1A1SMN1; SMN2MEN1MAPT | |
| SCHEMBL30085037 | 0.78 | HRH3 (0.40) | HRH3 | |
| SCHEMBL16194551 | 0.78 | HSD17B10 (0.42) | HRH3SMN1; SMN2SLC6A1 | |
| SCHEMBL9893052 | 0.78 | TERT (0.41) | HRH3ALDH1A1TSHRMEN1KMT2A | |
| SCHEMBL15025236 | 0.78 | HSD17B10 (0.42) | HRH3SMN1; SMN2SLC6A1 | |
| SCHEMBL28071534 | 0.75 | SLC6A1 (0.39) | HRH3SLC6A1 | |
| SCHEMBL14472558 | 0.71 | HRH3 (0.39) | HRH3SLC6A1SLC6A9 | |
| SCHEMBL15723663 | 0.71 | HSD17B10 (0.49) | ALDH1A1SMN1; SMN2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120142677-A1 | Pyrrolidine Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142677-A1 | Pyrrolidine Compounds Which Modulate The CB2 Receptor | CNR2, CNR1, OPRL1 | HRH3 236/4885PLA2G10 1414/4885PLA2G5 853/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.